483 Safety and Efficacy of Endoscopic Ultrasound Guided Radiofrequency Ablation (Eus-Rfa) in the Treatment of Pancreatic Lesions: A Multi-Center Experience

Thosani, Nirav; Sharma, Neil; Raijman, Isaac; Thosani, Amar; Kannadath, Bijun S.; Guider, Julie; Raza, Ali; Guha, Sushovan

doi:10.1016/j.gie.2018.04.092

Cited by 16 publications

(19 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After literature search and review of titles and abstracts, 12 articles describing 61 patients and 73 P-NETs met our pre-defined inclusion criteria 6 7 8 9 10 11 12 13 14 15 16 17 . Table 1 summarizes findings from all studies reporting the feasibility, effectiveness and safety of EUS-RFA in the treatment of P-NETs.…”

Section: Resultsmentioning

confidence: 99%

Endoscopic ultrasound-guided radiofrequency ablation of pancreatic neuroendocrine tumors: a systematic review of the literature

Imperatore

Nucci²,

Mandelli³

et al. 2020

Endosc Int Open

View full text Add to dashboard Cite

Background and study aims Surgery is the mainstay therapy for pancreatic neuroendocrine tumors (P-NETs), but it is associated with significant adverse events (AEs). In recent years, endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) has been described for treating P-NETs. We performed a systematic literature review aimed at exploring the feasibility, effectiveness, and safety of EUS-RFA in treatment of P-NETs. Methods The literature review was performed in PubMed/MEDLINE, EMBASE, and SCOPUS to identify all case reports of EUS-RFA for treatment of P-NETs. Results Sixyt-one patients (males 49.2 %, mean age 64.5 years) and 73 tumors (mean size 16 mm, insulinomas 30.1 %) treated with EUS-RFA were included from 12 studies. The overall effectiveness of EUS-RFA was 96 % (75 % – 100 %) without differences between functional vs. non-functional P-NETs (P = 0.3) and without relevant issues about safety (mild AEs 13.7 %). While tumor location was not predictive for incomplete/non-response to EUS-RFA, greater tumor dimensions predicted treatment failure (21.8 ± 4.71 mm in the non-response group vs 15.07 ± 7.34 mm in the response group, P = 0.048). At ROC analysis, a P-NET size cut-off value ≤18 mm predicted response to treatment, with a sensitivity of 80 % (95 % CI 28.4 % – 99.5 %), a specificity of 78.6 % (95 % CI 63.2 % – 89.7 %), a positive predictive value of 97.1 % (95 % CI 84.7 % – 99.9 %) and a negative predictive value of 30.8 % (95 % CI 9.1 % – 61.4 %), with an area under the curve of 0.81 (95 % CI 0.67 – 0.95). Conclusions EUS-RFA is safe and effective for treating P-NETs. It may be reasonable to consider EUS-RFA for small P-NETs, irrespective of the functional status.

show abstract

Section: Resultsmentioning

confidence: 99%

Endoscopic ultrasound-guided radiofrequency ablation of pancreatic neuroendocrine tumors: a systematic review of the literature

Imperatore

Nucci²,

Mandelli³

et al. 2020

Endosc Int Open

View full text Add to dashboard Cite

show abstract

“…From an initial pool of 84 studies, 13 studies reported use of EUS-RFA in pancreatic lesions 1 3 4 7 8 9 10 11 12 13 14 15 16 . The schematic diagram of study selection as per PRISMA guidelines is illustrated in Fig.…”

Section: Resultsmentioning

confidence: 99%

“…Functional PNETs exhibited a sustained attenuation of clinical symptoms such as hypoglycemia or diarrhea, rapid normalization of secreted hormone levels, and sustained significant decrease in size of the neoplasm. PNETs had a pooled clinical success rate ranging from 83 % to 100 % 10 11 12 13 .…”

Section: Discussionmentioning

confidence: 99%

“…Two types of RFA probes were used in our meta-analysis. A STARmed needle of different sizes (18 G/19 G/22 G) was most commonly used to deliver RFA energy 3 4 7 8 9 10 11 12 . This operative needle is associated with a pump cooling the needle with help of chilled saline which prevents charring of the tip and improves accuracy of ablation.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of EUS-RFA in pancreatic tumors: Is it ready for prime time? A systematic review and meta-analysis

et al. 2020

View full text Add to dashboard Cite

Background and study aims Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) can be used in patients with unresectable pancreatic ductal adenocarcinoma (PDAC). We performed a systematic review and meta-analysis to evaluate the efficacy of EUS-RFA in treatment of locally advanced unresectable PDAC and other pancreatic tumors. Patients and methods A comprehensive search was done of multiple electronic databases and conference proceedings including PubMed, EMBASE, Web of Science databases, Google Scholar and manual search of references (from inception through May 2019) to identify the studies reporting use of EUS-RFA for pancreatic lesions. The primary outcome was to evaluate technical and clinical success of the procedure. The secondary outcome was to study overall adverse events (AEs). Results Thirteen studies reporting 165 EUS-RFA procedures on 134 patients were included. Of 134 patients, 27.94 % (38) had unresectable locally advanced PDAC, 40 % (53) had PNETs, 3 % (4) had metastasis to the pancreas and 30 % (41) had other lesions. The pooled technical success rate calculated out of the total number of procedures was 100 % (95 % CI [99.18 – 100], I2 = 0 %). The pooled clinical success rate calculated out of the total number of patients was 91.58 % (95 % CI [82.5 – 98.08], I2 = 21.5 %). The pooled overall AE rates were 14.67 % (95 % CI [4.77 – 27.46], I2 = 56.19 %) out of which abdominal pain was the most common with 9.82 % (95 % CI [3.34 – 18.24], I2 = 23.76 %). Low to moderate heterogeneity was noted. Conclusion EUS-RFA has high technical (100 %) and clinical success (91.5 %) rates. Further multicenter trials are needed to further validate our findings.

show abstract

“…To date, only a few case reports and small case series (1 – 12 patients) have described the feasibility, effectiveness and safety of EUS-guided RFA treatment of P-NET 4 5 6 7 8 9 10 11 12 13 14 . We report 11 cases of P-NET managed in a single tertiary center, with the aim of exploring the effectiveness and safety of EUS-RFA in treatment of P-NET.…”

Section: Introductionmentioning

confidence: 99%

Endoscopic ultrasound-guided radiofrequency ablation of pancreatic neuroendocrine tumors: a case series

Nucci¹,

Imperatore

Mandelli³

et al. 2020

Endosc Int Open

View full text Add to dashboard Cite

Background and study aims Surgery is the considered the therapeutic cornerstone for pancreatic neuroendocrine tumors (P-NETs), although burdened by high risk of significant adverse events. Recently, endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) has been described for P-NETs. We aimed to evaluate the effectiveness and safety of EUS-RFA for treatment of P-NETs. Patients and methods We prospectively included all consecutive patients with P-NET ≤ 20 mm who were treated with EUS-RFA and were followed-up for at least 12 months. Results Ten patients (5 males, mean age 78.6 years, mean body mass index 28.2) with 11 P-NETs (mean size 14.5 mm; range 9 – 20 mm) localized in the pancreatic head (3 lesions), pancreatic body (5 lesions), and tail (3 lesions) underwent complete EUS ablation with one session of RFA. Complete ablation of P-NET was reached using a single-session RFA with a mean of 2.3 treatment applications per session. At both 6 – and 12-months computed tomography scans, all the patients had complete disappearance of lesions with radiological normalization. Regarding safety, only two cases of mild abdominal pain were recorded in two subjects with pancreatic head lesion, which were effectively treated with analgesics. The mean duration of hospital stay was 4 days (range 3 – 7 days). Conclusions EUS-RFA is effective and safe in treating P-NETs. It may be considered an effective therapeutic option in the treatment of small P-NETs independently from their functional status.

show abstract

483 Safety and Efficacy of Endoscopic Ultrasound Guided Radiofrequency Ablation (Eus-Rfa) in the Treatment of Pancreatic Lesions: A Multi-Center Experience

Cited by 16 publications

References 0 publications

Endoscopic ultrasound-guided radiofrequency ablation of pancreatic neuroendocrine tumors: a systematic review of the literature

Endoscopic ultrasound-guided radiofrequency ablation of pancreatic neuroendocrine tumors: a systematic review of the literature

Efficacy of EUS-RFA in pancreatic tumors: Is it ready for prime time? A systematic review and meta-analysis

Endoscopic ultrasound-guided radiofrequency ablation of pancreatic neuroendocrine tumors: a case series

Contact Info

Product

Resources

About